Full-Time

Xenium Sales Specialist

Posted on 12/10/2024

10x Genomics

10x Genomics

1,001-5,000 employees

Biotechnology tools for genomic research

Compensation Overview

$133.7k - $180.9kAnnually

+ Equity Grants + Annual Bonus Program

Senior

Pleasanton, CA, USA

The territory includes the Americas Region, and candidates from different regions within the US are considered.

Category
Field Sales
Sales & Account Management
Required Skills
Sales
Requirements
  • Bachelor’s degree in Biology, Molecular Biology, Biochemistry or related field; or the equivalent knowledge and experience.
  • Minimum of 6 years sales experience in Life Science, with significant capital equipment experience.
  • Proven success in selling capital equipment.
  • Ability to travel as needed to be successful in this field-based role, expected to be at least 50% of the time within the territory.
Responsibilities
  • Demonstrates technical credibility to consult with customers on technology solutions.
  • Exceptional funnel management skills with strong hunting/prospecting and closing skills.
  • Commitment to rigorous territory planning, market knowledge, both accurate and timely forecasting.
  • Develops and manages to a business plan to meet or exceed business goals for the assigned territory.
  • Understands the scientific projects and business needs of the customer to win the business.
  • Consistently and accurately manages the sales process including sales forecasting, pipeline management, and sales tracking through the use of the CRM system and other designated IT tools.
  • Develops and maintains current knowledge of the spatial/in-situ markets, products, and buying practices required to effectively compete in the assigned territory.
  • Strong communication skills in order to keep both internal and external stakeholders informed.
  • Utilizes product and application knowledge across the in situ portfolio to successfully conduct selling presentations and close instrument and reagent sales.
  • Ability to work collaboratively with the other members of the field organization.
  • Work with distributors to drive the Xenium technology (as needed) inclusive of training and joint travel days.
  • Represent the company professionally, ethically, and morally at all times.
Desired Qualifications
  • A Master’s or PhD degree is desirable.
  • Strong desire to win business and establish long term customer relationships.

10x Genomics provides tools and technologies for genomic research, focusing on single-cell analysis, spatial gene expression, and immune profiling. Their products enable researchers to analyze genetic information in detail, which is crucial for understanding complex biological systems and advancing personalized medicine. The company differentiates itself by offering high-quality laboratory equipment, consumables, and software solutions, along with ongoing support for clients in the life sciences sector. The goal of 10x Genomics is to empower researchers to explore the complexities of the human genome and drive advancements in medical research.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Pleasanton, California

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for spatial transcriptomics boosts 10x Genomics' market potential in cancer research.
  • Multi-omics approaches create opportunities for expanding 10x Genomics' product lines and services.
  • AI-driven data analysis tools enhance efficiency, complementing 10x Genomics' software solutions.

What critics are saying

  • Increased competition from emerging biotech companies may erode 10x Genomics' market share.
  • Ongoing patent disputes with companies like Parse Biosciences pose litigation risks.
  • Rapid technological advancements require continuous innovation to maintain 10x Genomics' competitive edge.

What makes 10x Genomics unique

  • 10x Genomics offers unique single-cell and spatial analysis tools for detailed genomic research.
  • Their robust patent portfolio protects innovative technologies from competitors like Parse Biosciences.
  • 10x Genomics' integrated solutions include instruments, consumables, and software for comprehensive genomic analysis.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health benefits

Generous time off

Parental leave

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Stock Titan
Mar 6th, 2025
Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer

Cardillo joins from 10x Genomics, where she served as Vice President of Corporate Communications.

PR Newswire
Mar 3rd, 2025
10X Genomics Secures Injunction Against Parse Biosciences' Planned Atac Products

10x Genomics' ATAC-Seq patents found valid and infringedPLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, 2025, in the United States District Court for the District of Delaware, Parse agreed - a week before trial was to start - to a worldwide permanent injunction that prevents it from making, using, selling or offering for sale its planned ATAC and ATAC-Multiome Single Cell products. As part of this consent agreement, Parse admitted that 10x's ATAC-seq patents are valid, enforceable and infringed by Parse's use of ATAC-seq methods and compositions."This development further validates the strength of our broad patent portfolio, which helps protect and preserve the world-class innovation engine at 10x," said Eric S. Whitaker, Chief Legal Officer of 10x Genomics. "We are pleased with this resolution on ATAC as we continue to defend the asserted Brenner patents on appeal."The company's litigation against Parse's gene expression products remains ongoing, with additional asserted patents under appeal. Following entry of the injunction, the trial scheduled for March 2025 concerning 10x's remaining patent infringement claims against Parse has been stayed pending those appeals.10x Genomics is committed to defending its intellectual property and investing in groundbreaking technologies that empower researchers worldwide.About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health

PR Newswire
Feb 23rd, 2025
10X Genomics Unveils Innovation Roadmap At Agbt General Meeting, Advancing Leadership In Large-Scale Single Cell And Spatial Analysis

New single cell and spatial innovations extend 10x Genomics' technology and performanceleadership across all three platformsPLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new product innovations to solidify its position as the best partner for high-performance single cell research at scale. In addition, the company unveiled a robust new product roadmap for its Visium and Xenium portfolios, extending its performance and technology leadership in the rapidly growing field of spatial biology."After a record year of innovation, we continue to push the boundaries of what's possible in single cell and spatial biology, taking on the hardest challenges so researchers can make the biggest impact," said Ben Hindson, Co-Founder and Chief Scientific Officer of 10x Genomics. "Our 2025 roadmap will once again raise the bar for the field and enable researchers to tackle bigger questions, analyze more samples and extract deeper insights from their data."10x Genomics will host a workshop at AGBT today, Sunday, February 23, at 1 p.m. ET to share the latest data and development directions across its three platforms

PR Newswire
Feb 18th, 2025
10X Genomics To Participate In The 45Th Annual Td Cowen Health Care Conference

PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, at 11:10 a.m. Eastern Time.Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 45 days after the event.About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables, and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology

PR Newswire
Jan 12th, 2025
10X Genomics Announces Preliminary Select Fourth Quarter And Full Year 2024 Results

FY 2024 revenue of ~$611 million and Q4 2024 revenue of ~$165 million, representing 9% growth sequentiallyPLEASANTON, Calif., Jan. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2024.Preliminary, Unaudited Select Fourth Quarter 2024 Financial ResultsRevenue of approximately $165.0 million for the three months ended December 31, 2024 , representing 9% growth sequentially and a 10% decrease as compared to the corresponding prior year period.for the three months ended , representing 9% growth sequentially and a 10% decrease as compared to the corresponding prior year period. Instruments revenue of approximately $24.4 million , representing 28% growth sequentially and a 37% decrease as compared to the corresponding prior year period. Instruments revenue consists of approximately $10.9 million of Chromium instruments revenue and $13.4 million of Spatial instruments revenue., representing 28% growth sequentially and a 37% decrease as compared to the corresponding prior year period. Instruments revenue consists of approximately of Chromium instruments revenue and of Spatial instruments revenue

INACTIVE